logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers 3
  • 1
    Fuller, Mark Alan
    Director born in December 1973
    Individual (1 offspring)
    Officer
    2017-12-12 ~ now
    OF - Director → CIF 0
    Mr Mark Alan Fuller
    Born in December 1973
    Individual (1 offspring)
    Person with significant control
    2017-12-12 ~ now
    PE - Ownership of shares – 75% or moreCIF 0
  • 2
    Lee De'ath
    Individual (1 offspring)
    Insolvency
    2019-08-14 ~ now
    IP - (Case 1) practitioner → CIF 0
  • 3
    Bai Cham
    Individual (487 offsprings)
    Insolvency
    2019-08-14 ~ now
    IP - (Case 1) practitioner → CIF 0
parent relation
Company in focus

MARK FULLER PHARMA CONSULTING LTD

Period: 2017-12-12 ~ 2021-12-27
Company number: 11108596
Registered name
MARK FULLER PHARMA CONSULTING LTD - Dissolved
Standard Industrial Classification
70229 - Management Consultancy Activities Other Than Financial Management
Brief company account
Please be reminded the displayed account data is older than 4 years hence might not reflect current company status.
Par Value of Share
Class 1 ordinary share
12017-12-12 ~ 2019-04-30
Debtors
256 GBP2019-04-30
Cash at bank and in hand
97,541 GBP2019-04-30
Current Assets
97,797 GBP2019-04-30
Creditors
Current
45,406 GBP2019-04-30
Net Current Assets/Liabilities
52,391 GBP2019-04-30
Total Assets Less Current Liabilities
52,391 GBP2019-04-30
Equity
Called up share capital
100 GBP2019-04-30
Retained earnings (accumulated losses)
52,291 GBP2019-04-30
Equity
52,391 GBP2019-04-30
Average Number of Employees
12017-12-12 ~ 2019-04-30
Property, Plant & Equipment - Disposals
Computers
-1,218 GBP2017-12-12 ~ 2019-04-30
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Computers
373 GBP2017-12-12 ~ 2019-04-30
Property, Plant & Equipment - Decrease in depreciation and impairment related to disposals
Computers
-373 GBP2017-12-12 ~ 2019-04-30
Trade Debtors/Trade Receivables
Current
66 GBP2019-04-30
Debtors
Current, Amounts falling due within one year
256 GBP2019-04-30
Corporation Tax Payable
Current
42,780 GBP2019-04-30
Accrued Liabilities
Current
850 GBP2019-04-30
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
100 shares2019-04-30
Profit/Loss
Retained earnings (accumulated losses)
182,291 GBP2017-12-12 ~ 2019-04-30
Dividends Paid
Retained earnings (accumulated losses)
-130,000 GBP2017-12-12 ~ 2019-04-30

  • MARK FULLER PHARMA CONSULTING LTD
    Info
    Registered number 11108596
    Cvr Global Llp Town Wall House, Balkerne Hill, Colchester, Essex CO3 3AD
    PRIVATE LIMITED COMPANY incorporated on 2017-12-12 and dissolved on 2021-12-27 (4 years). The status of the company number is Dissolved.
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 22 April 2026 and licensed under the Open Government Licence v3.0.